MARSHALL WACE ASIA Ltd Purchases New Position in Alexion Pharmaceuticals, Inc. (ALXN)

MARSHALL WACE ASIA Ltd purchased a new stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 35,528 shares of the biopharmaceutical company’s stock, valued at approximately $4,939,000.

A number of other hedge funds have also modified their holdings of the business. Bain Capital Public Equity Management LLC increased its stake in shares of Alexion Pharmaceuticals by 23.2% during the 2nd quarter. Bain Capital Public Equity Management LLC now owns 70,753 shares of the biopharmaceutical company’s stock worth $8,784,000 after purchasing an additional 13,318 shares during the last quarter. Brown Advisory Inc. increased its stake in shares of Alexion Pharmaceuticals by 297.9% during the 2nd quarter. Brown Advisory Inc. now owns 20,261 shares of the biopharmaceutical company’s stock worth $2,516,000 after purchasing an additional 15,169 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. increased its stake in shares of Alexion Pharmaceuticals by 146.8% during the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 36,237 shares of the biopharmaceutical company’s stock worth $5,037,000 after purchasing an additional 21,555 shares during the last quarter. Honeywell International Inc. increased its stake in shares of Alexion Pharmaceuticals by 42.3% during the 3rd quarter. Honeywell International Inc. now owns 127,600 shares of the biopharmaceutical company’s stock worth $17,738,000 after purchasing an additional 37,900 shares during the last quarter. Finally, DNB Asset Management AS increased its stake in shares of Alexion Pharmaceuticals by 3.7% during the 3rd quarter. DNB Asset Management AS now owns 27,175 shares of the biopharmaceutical company’s stock worth $3,778,000 after purchasing an additional 967 shares during the last quarter. Hedge funds and other institutional investors own 93.33% of the company’s stock.

ALXN traded down $2.04 on Friday, reaching $119.00. The company had a trading volume of 8,172 shares, compared to its average volume of 1,069,123. Alexion Pharmaceuticals, Inc. has a fifty-two week low of $102.10 and a fifty-two week high of $140.77. The firm has a market cap of $27.28 billion, a P/E ratio of 23.16, a price-to-earnings-growth ratio of 1.05 and a beta of 1.02. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.74 and a current ratio of 3.16.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Wednesday, October 24th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the Zacks’ consensus estimate of $1.74 by $0.28. Alexion Pharmaceuticals had a net margin of 3.90% and a return on equity of 16.60%. The business had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same quarter in the prior year, the business earned $1.44 EPS. Alexion Pharmaceuticals’s quarterly revenue was up 19.5% on a year-over-year basis. As a group, equities analysts forecast that Alexion Pharmaceuticals, Inc. will post 6.82 earnings per share for the current year.

Several research analysts have recently weighed in on ALXN shares. BidaskClub lowered shares of Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, August 15th. Stifel Nicolaus boosted their price objective on shares of Alexion Pharmaceuticals from $130.00 to $136.00 and gave the stock a “hold” rating in a research note on Tuesday, September 25th. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, October 5th. Citigroup boosted their price objective on shares of Alexion Pharmaceuticals from $173.00 to $195.00 and gave the stock a “buy” rating in a research note on Tuesday, September 25th. Finally, ValuEngine lowered shares of Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 4th. Three research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $161.50.

In related news, EVP Indrani Lall Franchini sold 2,605 shares of the company’s stock in a transaction dated Wednesday, November 28th. The shares were sold at an average price of $118.13, for a total value of $307,728.65. Following the transaction, the executive vice president now owns 29,304 shares in the company, valued at approximately $3,461,681.52. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 4.35% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This news story was reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://transcriptdaily.com/2018/12/07/marshall-wace-asia-ltd-purchases-new-position-in-alexion-pharmaceuticals-inc-alxn.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

Read More: Market Capitalization

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply